中国前列腺癌患者TMPRSS2::ETS融合基因发生率的meta分析

doi:10.3969/j.issn.1004-616x.2022.05.003

摘要/Abstract

摘要： 目的：通过meta分析研究中国前列腺癌患者中 TMPRSS2::ETS融合基因的发生率。方法：通过PubMed、Web of Science、Google Scholar、中国知识资源总库(CNKI)、万方医学在线数据库和维普数据库进行系统检索。用QUADAS-2评估偏倚风险，并用Stata 12.0和Review Manager 5.3进行meta分析，评估 TMPRSS2::ETS融合基因在中国前列腺癌患者中的发生率。结果：共纳入16项研究，发现在中国前列腺癌患者中 TMPRSS2::ERG融合基因是 TMPRSS2::ETS融合基因家族最主要的类型，其发生率为 16.7%，95%可信区间为(14.5%，18.8%)。就样本类型而言，穿刺活检样本的融合基因发生率为 17.9%，95%可信区间为(15.8%，20.1%)；当使用免疫组化检测技术时，融合基因发生率为 16.6%，95%可信区间为(13.0%，20.2%)。结论：中国前列腺癌患者中，TMPRSS2::ERG融合基因为主要类型，但其发生率较低，因此不宜将TMPRSS2::ERG融合基因作为国内前列腺癌患者的诊断标志。

关键词: 前列腺癌, TMPRSS2::ETS融合基因, 中国人群, meta分析

Abstract: OBJECTIVE: To use meta-analysis for assessing the occurrence of TMPRSS2::ERG fusion gene in Chinese patients with prostate cancer.METHODS: A systematic search was conducted through PubMed,Web of Science,Google Scholar,China knowledge Resource Database (CNKI),Wanfang Medical online Database and VIP Database.The risk of bias was assessed using QUADAS-2 and a meta-analysis was performed using Stata12.0 and Review Manager 5.3 to evaluate the occurrence of TMPRSS2::ERG fusion gene in Chinese prostate cancer patients.RESULTS: A total of 16 articles were included.The incidence rate of TMPRSS2::ERG fusion gene in prostate cancer was 16.7%[95% CI (14.5%,18.8%)].Regarding the type of samples,biopsy specimens showed the incidence rate of fusion gene was 17.9%[95% CI (15.8%,20.1%)].When using immunohistochemistry (IHC) detection technology,the incidence rate of fusion gene was 16.6%[95% CI (13.0%,20.2%)].CONCLUSION: The occurrence of TMPRSS2::ERG fusion gene was low in Chinese prostate cancer patients,therefore,the TMPRSS2::ERG fusion gene cannot be used as a diagnostic marker for Chinese prostate cancer patients.

Key words: prostate cancer, TMPRSS2::ETS fusion gene, Chinese population, meta-analysis

中图分类号:

R596.2

张嘉蔚, 袁琴, 徐贤荣, 方学贤, 曹亦菲, 杨军. 中国前列腺癌患者TMPRSS2::ETS融合基因发生率的meta分析[J]. 癌变·畸变·突变, 2022, 34(5): 344-352.

ZHANG Jiawei, YUAN Qin, XU Xianrong, FANG Xuexian, CAO Yifei, YANG Jun. Occurrence of the TMPRSS2::ETS fusion gene in Chinese patients with prostate cancer: a meta-analysis[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(5): 344-352.

参考文献

[1] FERLAY J, SHIN H R, BRAY F, et al. Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008[J]. Int J Cancer, 2010, 127(12):2893-2917.
[2] VELONAS V M, WOO H H, DOS REMEDIOS C G, et al. Current status of biomarkers for prostate cancer[J]. Int J Mol Sci, 2013, 14(6):11034-11060.
[3] TOMLINS S A, RHODES D R, PERNER S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer[J]. Science, 2005, 310(5748):644-648.
[4] 孙文国,夏利,蒋雷鸣,等. TMPRSS2-ERG、AMACR和p63在前列腺癌中的表达及相关性[J].安徽医科大学学报, 2012, 47(11):1351-1355.
[5] MAO X Y, YU Y W, BOYD L K, et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis[J]. Cancer Res, 2010, 70(13):5207-5212.
[6] QI M, YANG X Q, ZHANG F, et al. ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients[J]. PLoS One, 2014, 9(2):e84959.
[7] SUN Q P, LI L Y, CHEN Z, et al. Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the early diagnosis of prostate cancer[J]. J Mol Diagn, 2010, 12(5):718-724.
[8] XU C Q, LUO J D, WANG M M, et al. Detection of tmprss2-erg and tmprss2-egr1 gene fusion in prostate cancer from a Chinese population[J]. Egypt J Med Hum Genet, 2020, 21(1):1-8.
[9] LEYTEN G H J M, HESSELS D, JANNINK S A, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer[J]. Eur Urol, 2014, 65(3):534-542.
[10] WHITING P F, RUTJES A W S, WESTWOOD M E, et al. QUADAS-2:a revised tool for the quality assessment of diagnostic accuracy studies[J]. Ann Intern Med, 2011, 155(8):529-536.
[11] JIANG B H, SEDARSKY J, SRIVASTAVA S, et al. ERG tumor type is less frequent in high grade and high stage prostate cancers of Chinese men[J]. J Cancer, 2019, 10(9):1991-1996.
[12] 肖立,殷于磊,陈燕,等.穿刺活检前列腺癌ERG基因重排分析[J].临床与实验病理学杂志, 2015, 31(10):1110-1114.
[13] WANG M, GAO W, LU D H, et al. miR-1271 inhibits cell growth in prostate cancer by targeting ERG[J]. Pathol Oncol Res, 2018, 24(2):385-391.
[14] JIANG H, MAO X Y, HUANG X Y, et al. TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer[J]. Tumor Biol, 2016, 37(9):12397-12402.
[15] REN S C, PENG Z Y, MAO J H, et al. RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings[J]. Cell Res, 2012, 22(5):806-821.
[16] KONG D P, CHEN R, ZHANG C L, et al. Prevalence and clinical application of TMPRSS2-ERG fusion in Asian prostate cancer patients:a large-sample study in Chinese people and a systematic review[J]. Asian J Androl, 2020, 22(2):200-207.
[17] DONG J, XIAO L, SHENG L, et al. TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China[J]. Asian Pac J Cancer Prev, 2014, 15(7):3099-3103.
[18] 陶晶,张豪杰,肖立,等. TMPRSS2-ERG融合基因在国人前列腺癌组织中的表达及其临床意义[J].中国男科学杂志, 2016, 30(12):16-20.
[19] 郭琦,余英豪.前列腺癌中TMPRSS2-ERG融合基因和ERG蛋白表达及其意义[J].临床与实验病理学杂志, 2014, 30(10):1099-1103.
[20] 潘秀懿,谭珺娅,聂玲,等.前列腺癌ERG基因重排与蛋白表达及其与预后的关系[J].四川大学学报(医学版), 2017, 48(1):66-70.
[21] NIE L, PAN X Y, ZHANG M N, et al. The expression profile and heterogeneity analysis of ERG in 633 consecutive prostate cancers from a single center[J]. Prostate, 2019, 79(8):819-825.
[22] 杨子萱. ERG在前列腺癌和血管源性肿瘤中的表达及其临床应用价值[D].武汉:华中科技大学, 2013.
[23] ZENG W, SUN H Y, MENG F K, et al. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer[J]. Int J Clin Exp Pathol, 2015, 8(2):1878-1888.
[24] 李艳菊,张春莉,杨彦玲,等. TMPRSS2-ERG、P504S、P63和34βE12在前列腺癌中表达与临床意义[J].延安大学学报:医学科学版, 2017, 15(2):22-24.
[25] CHANDRA H S, HEISTERKAMP N C, HUNGERFORD A, et al. Philadelphia Chromosome Symposium:commemoration of the 50th anniversary of the discovery of the Ph chromosome[J]. Cancer Genet, 2011, 204(4):171-179.
[26] RUBIN M A. ETS rearrangements in prostate cancer[J]. Asian J Androl, 2012, 14(3):393-399.
[27] ZHOU C K, YOUNG D, YEBOAH E D, et al. TMPRSS2:ERG gene fusions in prostate cancer of west African men and a Meta-analysis of racial differences[J]. Am J Epidemiol, 2017, 186(12):1352-1361.
[28] KIMURA T, FURUSATO B, MIKI J, et al. 470 expression of erg oncoprotein is less frequently and associated with a less aggressive tumor phenotype in Japanese prostate cancer patients[J]. J Urol, 2012, 187(4):e192-e193.
[29] MIYAGI Y, SASAKI T, FUJINAMI K, et al. ETS familyassociated gene fusions in Japanese prostate cancer:analysis of 194 radical prostatectomy samples[J]. Mod Pathol, 2010, 23(11):1492-1498.
[30] SUH J H, PARK J W, LEE C, et al. ERG immunohistochemistry and clinicopathologic characteristics in Korean prostate adenocarcinoma patients[J]. Korean J Pathol, 2012, 46(5):423-428.
[31] TOMLINS S A, PALANISAMY N, SIDDIQUI J, et al. Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases:ERG staining in prostate core biopsies[J]. Arch Pathol Lab Med, 2012, 136(8):935-946.
[32] BRAUN M, SCHEBLE V J, MENON R, et al. Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer[J]. Histopathology, 2011, 58(7):1028-1036.
[33] 向华,凌宗欣,孙柯,等.前列腺癌组织中TMPRSS2-ETS融合基因检测及其意义[J].中华病理学杂志, 2011, 40(3):187-188.